These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. The Pim kinases: new targets for drug development. Swords R; Kelly K; Carew J; Nawrocki S; Mahalingam D; Sarantopoulos J; Bearss D; Giles F Curr Drug Targets; 2011 Dec; 12(14):2059-66. PubMed ID: 21777193 [TBL] [Abstract][Full Text] [Related]
45. [The Pim family of protein kinases: structure, functions and roles in hematopoietic malignancies]. Zhukova IuN; Alekseeva MG; Zakharevich NV; Shtil' AA; Danilenko VN Mol Biol (Mosk); 2011; 45(5):755-64. PubMed ID: 22393773 [TBL] [Abstract][Full Text] [Related]
46. Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies. Szydłowski M; Garbicz F; Jabłońska E; Górniak P; Komar D; Pyrzyńska B; Bojarczuk K; Prochorec-Sobieszek M; Szumera-Ciećkiewicz A; Rymkiewicz G; Cybulska M; Statkiewicz M; Gajewska M; Mikula M; Gołas A; Domagała J; Winiarska M; Graczyk-Jarzynka A; Białopiotrowicz E; Polak A; Barankiewicz J; Puła B; Pawlak M; Nowis D; Golab J; Tomirotti AM; Brzózka K; Pacheco-Blanco M; Kupcova K; Green MR; Havranek O; Chapuy B; Juszczyński P Cancer Res; 2021 Dec; 81(23):6029-6043. PubMed ID: 34625423 [TBL] [Abstract][Full Text] [Related]
47. Insulin receptor substrate 1 is a substrate of the Pim protein kinases. Song JH; Padi SK; Luevano LA; Minden MD; DeAngelo DJ; Hardiman G; Ball LE; Warfel NA; Kraft AS Oncotarget; 2016 Apr; 7(15):20152-65. PubMed ID: 26956053 [TBL] [Abstract][Full Text] [Related]
48. Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL. Adam M; Pogacic V; Bendit M; Chappuis R; Nawijn MC; Duyster J; Fox CJ; Thompson CB; Cools J; Schwaller J Cancer Res; 2006 Apr; 66(7):3828-35. PubMed ID: 16585210 [TBL] [Abstract][Full Text] [Related]
49. Topical advances in PIM kinases and their inhibitors: Medicinal chemistry perspectives. Walhekar V; Bagul C; Kumar D; Muthal A; Achaiah G; Kulkarni R Biochim Biophys Acta Rev Cancer; 2022 May; 1877(3):188725. PubMed ID: 35367531 [TBL] [Abstract][Full Text] [Related]
50. Inhibition of PIM Kinases Promotes Neuroblastoma Cell Differentiation to a Neuronal Phenotype. Julson JR; Quinn CH; Bownes LV; Hutchins SC; Stewart JE; Aye J; Yoon KJ; Beierle EA J Pediatr Surg; 2023 Jun; 58(6):1155-1163. PubMed ID: 36907773 [TBL] [Abstract][Full Text] [Related]
51. The survival kinases Akt and Pim as potential pharmacological targets. Amaravadi R; Thompson CB J Clin Invest; 2005 Oct; 115(10):2618-24. PubMed ID: 16200194 [TBL] [Abstract][Full Text] [Related]
52. The role of PIM kinases in human and mouse CD4+ T cell activation and inflammatory bowel disease. Jackson LJ; Pheneger JA; Pheneger TJ; Davis G; Wright AD; Robinson JE; Allen S; Munson MC; Carter LL Cell Immunol; 2012; 272(2):200-13. PubMed ID: 22078270 [TBL] [Abstract][Full Text] [Related]
53. Deep PIM kinase substrate profiling reveals new rational cotherapeutic strategies for acute myeloid leukemia. Joglekar T; Chin A; Voskanian-Kordi A; Baek S; Raja A; Rege A; Huang W; Kane M; Laiho M; Webb TR; Fan X; Rubenstein M; Bieberich CJ; Li X Blood Adv; 2024 Aug; 8(15):3880-3892. PubMed ID: 38739710 [TBL] [Abstract][Full Text] [Related]
54. PIM kinase isoform specific regulation of MIG6 expression and EGFR signaling in prostate cancer cells. Siu A; Virtanen C; Jongstra J Oncotarget; 2011 Dec; 2(12):1134-44. PubMed ID: 22193779 [TBL] [Abstract][Full Text] [Related]